The Technical Analyst
Brickell Biotech, Inc. [BBI]
Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Biotechnology
Brickell Biotech, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.17% $2.35
/ 8 sep 2022 @ 00:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 7.08 mill |
| EPS: | -0.420 |
| P/E: | -5.60 |
| Earnings Date: | Aug 11, 2022 |
| SharesOutstanding: | 3.01 mill |
| Avg Daily Volume: | 0 mill |
| RATING 2023-03-30 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -5.60 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -5.60 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.984 - 2.72 ( +/- 15.57%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-05-17 | Hardy Reginald L | Buy | 65 000 | Stock Option (right to buy) |
| 2022-05-17 | Hardy Reginald L | Buy | 65 000 | Stock Option (right to buy) |
| 2022-05-17 | Samant Vijay B | Buy | 65 000 | Stock Option (right to buy) |
| 2022-05-17 | Lyons Gary A | Buy | 65 000 | Stock Option (right to buy) |
| 2022-05-17 | Lyons Gary A | Buy | 65 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 100.00 |
| Last 98 transactions |
| Buy: 10 056 470 | Sell: 193 721 |
Forecast:
01:40 - $3.68
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.35 (2.17% ) |
| Volume | 0.0313 mill |
| Avg. Vol. | 0 mill |
| % of Avg. Vol | 0 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BBI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BBI
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.
Latest Press Releases
2023-12-01 17:00:00 - Press Release
Fresh Tracks Therapeutics Announces Second Adjournment Of Special Meeting Of Stockholders
Meeting adjourned to december 15, 2023 at 10 a.m. mt
2023-11-17 08:30:00 - Press Release
Fresh Tracks Therapeutics Announces Adjournment Of Special Meeting Of Stockholders
Meeting adjourned to november 30, 2023 at 10 a.m. mt fresh tracks encourages all stockholders of record on october 17, 2023 who have not yet voted to do so by 11:59 p.m.
2023-11-13 08:30:00 - Press Release
Fresh Tracks Therapeutics Reports Third Quarter 2023 Financial Results And Provides Corporate Update
Cash and cash equivalents of approximately $11.5 million as of october 31, 2023 special meeting of stockholders on november 16 seeking stockholder approval of the dissolution and plan of dissolution if approved by stockholders, the company estimates that cash distributions in the dissolution will be between $5 million and $7 million, or $0.84 to $1.17 per share, to stockholders boulder, colo., nov. 13, 2023 (globe newswire) -- fresh tracks therapeutics, inc. (the “company” or “fresh tracks”) (nasdaq: frtx), today announced financial results for the third quarter ended september 30, 2023 and provided a corporate update.
2023-09-19 16:01:00 - Press Release
Fresh Tracks Therapeutics Announces Board Approval Of Plan Of Liquidation And Dissolution
Company intends to make cash distributions currently estimated to be between $5 million and $7 million, or $0.84 to $1.17 per share, to shareholders following shareholder approval and the filing of the certificate of dissolution company intends to make cash distributions currently estimated to be between $5 million and $7 million, or $0.84 to $1.17 per share, to shareholders following shareholder approval and the filing of the certificate of dissolution
2023-08-11 16:01:00 - Press Release
Fresh Tracks Therapeutics Reports Second Quarter 2023 Financial Results And Provides Corporate Update
Strengthened current cash position to approximately $15 million as of july 31, 2023 as a result of sale of future rights to event-based milestone and earnout payments on net sales of sofpironium bromide to botanix sb inc.
Latest News
2022-11-03 16:05:00 - GlobeNewsWire
Fresh Tracks Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 10, 2022
BOULDER, Colo., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (“Fresh Tracks Therapeutics” or the “Company”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company aiming to disrupt existing treatment paradigms by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it will report its third quarter financial results on Thursday, November 10th. Company management will host a conference call and webcast at 4:30 p.m. EST that same day to discuss the financial results and recent corporate highlights.
2022-08-11 18:27:28 - Seeking Alpha
Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q2 2022 Results - Earnings Call Transcript
Brickell Biotech, Inc. (NASDAQ:BBI ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Garth Russell - IR, LifeSci Advisors Robert Brown - Chief Executive Officer Monica Luchi - Chief Medical Officer Albert Marchio - Chief Financial Officer Deepak Chadha - Chief R&D Officer Conference Call Participants Ron Mather - Oppenheimer Thomas Flaten - Lake Street Operator Welcome everyone to the Brickell Biotech Second Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
2022-07-01 15:44:51 - Pulse2
Brickell Biotech (BBI) Stock: 1-For-45 Reverse Split Announced
Brickell Biotech, Inc. (Nasdaq: BBI) announced a 1-for-45 reverse split. These are the details.
2022-06-29 15:02:58 - InvestorPlace
Brickell Biotech (BBI) Stock Gains 50% Ahead of Meeting to Prevent Delisting
Delistings are commonplace in this bear market, however investors in Brickell Biotech and BBI stock are cheering some news today. The post Brickell Biotech (BBI) Stock Gains 50% Ahead of Meeting to Prevent Delisting appeared first on InvestorPlace.
2022-06-29 10:03:45 - PennyStocks
3 Penny Stocks To Watch After GDP Report
Penny stocks to buy or avoid right now? You decide after seeing the latest updates from 3 companies.
2022-06-09 19:20:07 - PennyStocks
Top Penny Stocks To Buy? 4 Biotech Stocks To Watch Now
2022-05-12 18:48:20 - Zacks Investment Research
Brickell (BBI) Reports Q1 Loss, Lags Revenue Estimates
Brickell (BBI) delivered earnings and revenue surprises of -33.33% and 52.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-05-12 18:35:06 - Seeking Alpha
Brickell Biotech, Inc.'s (BBI) CEO Robert Brown on Q1 2022 Results - Earnings Call Transcript
Brickell Biotech, Inc. (NASDAQ:BBI ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Garth Russell - IR, LifeSci Advisors Robert Brown - Chief Executive Officer Andrew Sklawer - Co-Founder and Chief Operating Officer Albert Marchio II - Chief Financial Officer Monica Luchi - Chief Medical Officer Conference Call Participants Trevor Allred - Oppenheimer Operator Greetings and welcome to Brickell Biotech Inc. Quarter 1, 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
2022-05-07 11:30:00 - PennyStocks
3 Strategies You Need to Know For Buying Penny Stocks
Can these penny stocks trading strategies make you money in 2022? The post 3 Strategies You Need to Know For Buying Penny Stocks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-05-05 16:01:00 - GlobeNewsWire
Brickell Biotech to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12, 2022
BOULDER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, announced today that it will report its first quarter financial results on Thursday, May 12th. Brickell's management will host a conference call and webcast at 4:30 p.m. EDT that same day to discuss the financial results and recent corporate highlights.